Kelly Barham, MD
Dermatology · Advance, NCNPI 1447454160
Payments from drug & device makers
Across 40 payments — averaging $25.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$575
- UCB, Inc.$64
- Medimetriks Pharmaceuticals, Inc.$57
- Pfizer$57
- Novartis$54
- Galderma Laboratories, L.p.$39
- plus $156 from 7 others
What the payments were for
- Food & beverage$98798%
- Education$152%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 22 | $575 |
| UCB, Inc. | 2 | $64 |
| Medimetriks Pharmaceuticals, Inc. | 1 | $57 |
| Pfizer | 3 | $57 |
| Novartis | 2 | $54 |
| Galderma Laboratories, L.p. | 2 | $39 |
| Sun Pharmaceutical Industries Inc. | 2 | $39 |
| Regeneron Healthcare Solutions, Inc. | 1 | $32 |
| LEO Pharma Inc. | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Botanix SB Inc | 1 | $17 |
| Revance Therapeutics, Inc. | 1 | $17 |
| Almirall LLC | 1 | $15 |
How this compares
$1,002 in reported general payments places this provider in the 30th percentile of 475 dermatology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OtezlaApremilast | 13 | $62,677 |
| Dupixent PenDupilumab | 12 | $46,551 |
| Dupixent SyringeDupilumab | 13 | $44,763 |
| Ivermectin | 11 | $3,084 |
| Fluorouracil | 34 | $3,031 |
| Acitretin | 13 | $2,282 |
| Clobetasol Propionate | 57 | $1,532 |
| Ketoconazole | 121 | $1,362 |
| Metronidazole | 25 | $1,321 |
| Tretinoin | 17 | $1,197 |
| Triamcinolone Acetonide | 99 | $1,140 |
| Ciclopirox | 22 | $787 |
| Doxycycline Hyclate | 46 | $720 |
| Finasteride | 42 | $564 |
| ValacyclovirValacyclovir Hcl | 32 | $420 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Advance
- Rosalyn GeorgeWilmington$6.5M
- Steven FeldmanWinston Salem$4.3M
- Adnan NasirRaleigh$4.1M
- Christopher SayedChapel Hill$3.3M
- Zoe DraelosHigh Point$3M
- Aida Lugo-SomolinosChapel Hill$2.2M
- Nicole SeminaraHuntersville$2.1M
- Sue Ellen CoxChapel Hill$1.8M
- Patrick McElgunnCharlotte$1.6M
- Kevin SteinWinston Salem$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.